Upgrades:
Microsoft (NASDAQ:MSFT) was upgraded by research analysts at HSBC from a “hold” rating to a “buy” rating in a note issued to investors on Thursday, MarketBeat Ratings reports. The brokerage presently has a $413.00 target price on the software giant’s stock, up from their prior target price of $347.00. HSBC’s price objective points to a potential upside of 25.22% from the stock’s current price.
A number of other analysts also recently weighed in on MSFT. Argus boosted their target price on shares of Microsoft from $371.00 to $390.00 and gave the stock a “buy” rating in a report on Monday, July 31st. StockNews.com initiated coverage on shares of Microsoft in a report on Thursday, October 5th. They issued a “buy” rating on the stock. Citigroup boosted their target price on shares of Microsoft from $420.00 to $430.00 and gave the stock a “buy” rating in a report on Thursday, October 19th. JPMorgan Chase & Co. restated an “overweight” rating and issued a $385.00 target price on shares of Microsoft in a report on Friday, September 22nd. Finally, The Goldman Sachs Group lifted their price target on shares of Microsoft from $400.00 to $450.00 and gave the stock a “buy” rating in a research note on Wednesday. Four analysts have rated the stock with a hold rating and thirty-five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $384.34. Read more …
Canadian Pacific Kansas City (NYSE:CP) (TSE:CP) was upgraded by investment analysts at Raymond James from a “market perform” rating to an “outperform” rating in a research note issued on Thursday, MarketBeat reports.
CP has been the subject of several other research reports. StockNews.com raised Canadian Pacific Kansas City from a “sell” rating to a “hold” rating in a research report on Thursday, October 5th. Morgan Stanley started coverage on Canadian Pacific Kansas City in a research note on Tuesday, September 5th. They set an “equal weight” rating and a $100.00 price objective for the company. Bank of America cut their price objective on Canadian Pacific Kansas City from $91.00 to $83.00 in a research note on Thursday, October 5th. CSFB lifted their price objective on shares of Canadian Pacific Kansas City from $87.00 to $88.00 and gave the company a “neutral” rating in a research report on Wednesday, August 9th. Finally, Barclays cut their target price on shares of Canadian Pacific Kansas City from $89.00 to $84.00 in a research note on Wednesday, October 4th. Five equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat, Canadian Pacific Kansas City currently has a consensus rating of “Moderate Buy” and a consensus price target of $98.22. Read more ...
Bristol-Myers Squibb (NYSE:BMY) was upgraded by stock analysts at HSBC from a “reduce” rating to a “hold” rating in a report issued on Friday, MarketBeat Ratings reports. The brokerage currently has a $53.00 price target on the biopharmaceutical company’s stock, down from their previous price target of $55.00. HSBC’s price objective points to a potential upside of 3.88% from the company’s current price.
Several other analysts also recently issued reports on the stock. UBS Group reaffirmed a “neutral” rating and set a $60.00 price objective (down from $70.00) on shares of Bristol-Myers Squibb in a report on Friday, October 20th. BMO Capital Markets decreased their target price on Bristol-Myers Squibb from $87.00 to $79.00 and set an “outperform” rating for the company in a research note on Friday, July 28th. Barclays decreased their target price on Bristol-Myers Squibb from $62.00 to $60.00 in a research note on Monday, October 2nd. SVB Leerink reissued a “market perform” rating on shares of Bristol-Myers Squibb in a report on Monday, July 10th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $75.00 price target on shares of Bristol-Myers Squibb in a report on Monday, October 9th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Bristol-Myers Squibb currently has a consensus rating of “Hold” and a consensus price target of $66.20. Read more …
Merck & Co., Inc. (NYSE:MRK) was upgraded by equities researchers at BMO Capital Markets from a “market perform” rating to an “outperform” rating in a research report issued on Friday, Marketbeat reports. The firm presently has a $132.00 target price on the stock. BMO Capital Markets’ target price points to a potential upside of 28.38% from the stock’s current price.
Other analysts have also recently issued reports about the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $135.00 price target on shares of Merck & Co., Inc. in a research note on Monday, October 23rd. UBS Group raised shares of Merck & Co., Inc. from a “neutral” rating to a “buy” rating and raised their price objective for the company from $117.00 to $122.00 in a research note on Friday, October 20th. StockNews.com started coverage on shares of Merck & Co., Inc. in a research note on Thursday, October 5th. They issued a “buy” rating on the stock. TheStreet cut shares of Merck & Co., Inc. from an “a-” rating to a “c+” rating in a research note on Friday, September 1st. Finally, Morgan Stanley reduced their price objective on shares of Merck & Co., Inc. from $116.00 to $115.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 11th. Five investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $125.65. Read more …
ResMed (NYSE:RMD) was upgraded by stock analysts at Morgan Stanley from an “equal weight” rating to an “overweight” rating in a research note issued on Friday, MarketBeat.com reports. The firm currently has a $169.00 price objective on the medical equipment provider’s stock, down from their previous price objective of $180.00. Morgan Stanley’s price target would indicate a potential upside of 25.51% from the stock’s current price.
Several other research firms have also weighed in on RMD. Royal Bank of Canada lowered ResMed from an “outperform” rating to a “sector perform” rating and reduced their price objective for the company from $273.00 to $202.00 in a research note on Thursday, October 12th. Needham & Company LLC raised ResMed from a “hold” rating to a “buy” rating in a research note on Wednesday, September 6th. Wolfe Research cut ResMed from an “outperform” rating to a “peer perform” rating in a research note on Friday, September 29th. Mizuho cut their price target on ResMed from $255.00 to $180.00 and set a “buy” rating on the stock in a report on Wednesday, September 13th. Finally, UBS Group lowered ResMed from a “buy” rating to a “neutral” rating in a report on Tuesday, September 5th. Four research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, ResMed currently has a consensus rating of “Moderate Buy” and an average price target of $204.56. Read more …
Downgrades:
Thermo Fisher Scientific (NYSE:TMO) was downgraded by research analysts at KeyCorp from an “overweight” rating to a “sector weight” rating in a research note issued to investors on Thursday, MarketBeat reports. KeyCorp also issued estimates for Thermo Fisher Scientific’s FY2023 earnings at $21.50 EPS.
TMO has been the topic of several other reports. Sanford C. Bernstein assumed coverage on shares of Thermo Fisher Scientific in a research note on Thursday, September 28th. They set an “outperform” rating and a $603.00 target price on the stock. Barclays decreased their price objective on shares of Thermo Fisher Scientific from $625.00 to $585.00 in a report on Friday, September 29th. JPMorgan Chase & Co. decreased their price target on shares of Thermo Fisher Scientific from $670.00 to $630.00 and set an “overweight” rating for the company in a report on Tuesday, October 17th. Wells Fargo & Company upgraded shares of Thermo Fisher Scientific from an “underweight” rating to an “equal weight” rating and set a $475.00 target price for the company in a research note on Wednesday. Finally, Royal Bank of Canada increased their price target on shares of Thermo Fisher Scientific from $662.00 to $698.00 in a research report on Thursday, July 27th. Two research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus price target of $593.94. Read more ...
Hershey (NYSE:HSY) was downgraded by stock analysts at TD Cowen from an “outperform” rating to a “market perform” rating in a research report issued to clients and investors on Friday, MarketBeat Ratings reports. They presently have a $200.00 target price on the stock, down from their prior target price of $235.00. TD Cowen’s price objective indicates a potential upside of 8.63% from the stock’s current price.
Other research analysts have also issued research reports about the company. Stephens assumed coverage on Hershey in a research report on Friday, October 13th. They set an “overweight” rating and a $240.00 price target on the stock. JPMorgan Chase & Co. cut their price target on Hershey from $252.00 to $249.00 in a research report on Wednesday, July 12th. StockNews.com assumed coverage on Hershey in a research report on Thursday, October 5th. They set a “hold” rating on the stock. Wells Fargo & Company cut their price target on Hershey from $260.00 to $240.00 and set an “equal weight” rating on the stock in a research report on Friday, July 28th. Finally, Barclays cut their price target on Hershey from $265.00 to $218.00 and set an “equal weight” rating on the stock in a research report on Thursday, October 12th. Eleven analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $251.24. Read more …
Bristol-Myers Squibb (NYSE:BMY – Get Free Report) was downgraded by stock analysts at BMO Capital Markets from an “outperform” rating to a “market perform” rating in a research report issued to clients and investors on Friday, MarketBeat.com reports. They currently have a $60.00 price objective on the biopharmaceutical company’s stock. BMO Capital Markets’ target price points to a potential upside of 17.60% from the stock’s previous close.
Other analysts have also recently issued reports about the stock. William Blair cut shares of Bristol-Myers Squibb from an “outperform” rating to a “market perform” rating in a report on Friday. UBS Group reiterated a “neutral” rating and issued a $60.00 price target (down previously from $70.00) on shares of Bristol-Myers Squibb in a research report on Friday, October 20th. SVB Leerink reiterated a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, July 10th. Bank of America decreased their price objective on shares of Bristol-Myers Squibb from $85.00 to $80.00 and set a “buy” rating for the company in a research note on Friday, July 28th. Finally, TD Cowen decreased their price objective on shares of Bristol-Myers Squibb from $80.00 to $66.00 and set a “market perform” rating for the company in a research note on Friday, September 15th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Bristol-Myers Squibb has a consensus rating of “Hold” and an average price target of $66.20. Read more …
Whirlpool (NYSE:WHR) was downgraded by equities research analysts at Longbow Research from a “buy” rating to a “neutral” rating in a note issued to investors on Friday, Marketbeat Ratings reports.
Several other equities analysts have also recently commented on the stock. Credit Suisse Group reaffirmed a “neutral” rating and set a $150.00 price objective on shares of Whirlpool in a research note on Tuesday, July 25th. Bank of America reduced their target price on shares of Whirlpool from $90.00 to $87.00 in a research report on Tuesday, July 18th. TheStreet lowered shares of Whirlpool from a “c” rating to a “d+” rating in a research note on Wednesday. Royal Bank of Canada raised their price target on shares of Whirlpool from $118.00 to $121.00 in a report on Wednesday, July 26th. Finally, StockNews.com started coverage on shares of Whirlpool in a report on Thursday, October 5th. They issued a “hold” rating on the stock. One research analyst has rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $125.20. Read more …
Comcast (NASDAQ:CMCSA) was downgraded by analysts at Scotiabank from a “sector outperform” rating to a “sector perform” rating in a research note issued to investors on Friday, MarketBeat.com reports. They presently have a $49.00 target price on the cable giant’s stock, down from their prior target price of $50.00. Scotiabank’s target price points to a potential upside of 23.61% from the company’s previous close.
Several other research firms also recently weighed in on CMCSA. Oppenheimer lifted their target price on Comcast from $48.00 to $55.00 in a research report on Friday, July 28th. Barclays raised their price target on Comcast from $42.00 to $47.00 and gave the company an “equal weight” rating in a research note on Monday, July 31st. Morgan Stanley raised their price target on Comcast from $48.00 to $50.00 and gave the company an “overweight” rating in a research note on Monday, July 24th. Wells Fargo & Company raised their price target on Comcast from $46.00 to $50.00 and gave the company an “equal weight” rating in a research note on Friday, July 28th. Finally, Sanford C. Bernstein started coverage on Comcast in a research note on Thursday, October 5th. They issued a “market perform” rating and a $46.00 target price on the stock. Nine equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Comcast presently has a consensus rating of “Moderate Buy” and an average price target of $49.00. Read more ...
Archive of Upgrades and Downgrades
Comments
Post a Comment